Association of Cohort and Individual Substance Use with Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission from Disorder: Findings from the World Mental Health Surveys

Louisa Degenhardt*, Chrianna Bharat, Meyer D. Glantz, Nancy A. Sampson, Ali Al-Hamzawi, Jordi Alonso, Laura H. Andrade, Brendan Bunting, Alfredo Cia, Giovanni De Girolamo, Peter De Jonge, Koen Demyttenaere, Oye Gureje, Josep Maria Haro, Meredith G. Harris, Yanling He, Hristo Hinkov, Aimee Nasser Karam, Elie G. Karam, Andrzej KiejnaViviane Kovess-Masfety, Victor Lasebikan, Sing Lee, Daphna Levinson, Maria Elena Medina-Mora, Zeina Mneimneh, Fernando Navarro-Mateu, Marina Piazza, José Posada-Villa, Kate Scott, Dan J. Stein, Hisateru Tachimori, Nathan Tintle, Yolanda Torres, Ronald C. Kessler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Importance: Limited empirical research has examined the extent to which cohort-level prevalence of substance use is associated with the onset of drug use and transitioning into greater involvement with drug use. Objective: To use cross-national data to examine time-space variation in cohort-level drug use to assess its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. Design, Setting, and Participants: The World Health Organization World Mental Health Surveys carried out cross-sectional general population surveys in 25 countries using a consistent research protocol and assessment instrument. Adults from representative household samples were interviewed face-to-face in the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. Data analysis was performed from July 2017 to July 2018. Main Outcomes and Measures: Data on timing of onset of lifetime drug use, DSM-IV drug use disorders, and remission from these disorders was assessed using the Composite International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as factors associated with these transitions. Results: Among the 90027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P <.001) and dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P <.001) and reduced probability of remission from abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P =.02). Birth cohort prevalence of drug use was also significantly associated with both initiation and illicit drug use transitions; for example, after controlling for individuals' experience of substance use and demographics, for each additional 10% of an individual's cohort using alcohol, a person's odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort's use of drug increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]). Conclusions and Relevance: Birth cohort substance use is associated with drug use involvement beyond the outcomes of individual histories of alcohol and other drug use. This has important implications for understanding pathways into and out of problematic drug use.

Original languageEnglish
Pages (from-to)708-720
Number of pages13
JournalJAMA Psychiatry
Volume76
Issue number7
DOIs
StatePublished - Jul 2019
Externally publishedYes

Funding

FundersFunder number
Argentinian Ministry of Health
Australian Government Department of Health and Ageing
Australian National Health and Medical Research Council1081984
European Economic Area Financial Mechanism
European Study
Federal Ministry of Health in Abuja
Fonds Gavoor Geluk
Health research council
Iraq Mental Health Survey
Israel National Health Survey
Ministry of Planning
Ministry of Public Health
Ministry of Social Protection
National Center for Public Health Protection
National Council on Science and Technology
National Institute of Health
National Institute of Psychiatry Ramon de la FuenteINPRFMDIES 4280
National Institutes of Health/Fogarty International CenterR03 TW006481-01
New Zealand Ministry of Health
Nigerian Survey of Mental Health and Wellbeing
Norwegian Financial Mechanism
South African Department of Health
São Paulo Megacity Mental Health Survey
US National Institute of Mental HealthR01-MH059575
US Public Health ServiceR01 DA016558, R13-MH066849, R01-MH069864
United Nations Development Group Iraq Trust Fund
United States National Institute of Mental HealthR01 MH070884
National Institute of Mental HealthU01-MH60220
National Institute on Drug AbuseR01DA044170
Substance Abuse and Mental Health Services Administration
Fogarty International CenterFIRCA R03-TW006481
Robert Wood Johnson Foundation044708
John D. and Catherine T. MacArthur Foundation
John W. Alden Trust
Eli Lilly and Company
GlaxoSmithKline
World Health Organization
University of Michigan
Pfizer Foundation
Japan Agency for Medical Research and Development
Pan American Health Organization
Ministerio de Sanidad, Consumo y Bienestar Social
Ministerio de Educación Superior, Ciencia y Tecnología, República DominicanaSAF 2000-158-CE
Medical Research Council
European CommissionQLG5-1999-01042, SANCO 2004123, EAHC 20081308
National Health and Medical Research Council1135991
Alcohol Advisory Council of New Zealand
Public Health Agency
Fundação de Amparo à Pesquisa do Estado de São Paulo03/00204-3
Generalitat de Catalunya2014 SGR 748, RETICS RD06/0011 REM-TAP, 2017 SGR 452, CB06/02/0046
Fonds Wetenschappelijk Onderzoek
National Insurance Institute of IsraelH25-SEISHIN-IPPAN-006, H16-KOKORO-013, H14-TOKUBETSU-026, H13-SHOGAI-023
Ministerio de Salud de la Nación
Ministry of Health, Labour and Welfare
Conselho Nacional de Desenvolvimento Científico e Tecnológico307784/2016-9
Israel National Institute for Health Policy Research
Instituto de Salud Carlos IIIFIS 00/0028
Università degli Studi del Piemonte Orientale
Norway Grants
Fundación para la Formación e Investigación Sanitarias de la Región de MurciaRO1-MH61905
Servicio Murciano de Salud
Regione Piemonte
Servier
Ministerio de SaludPL 0256
Ministerstwo Zdrowia

    Fingerprint

    Dive into the research topics of 'Association of Cohort and Individual Substance Use with Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission from Disorder: Findings from the World Mental Health Surveys'. Together they form a unique fingerprint.

    Cite this